Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: A North Central Cancer Treatment Group study

Journal of Clinical Oncology

Volumn 22, Issue 9, 2004, Pages 1572-1582

  Garrity, Megan M ^a   Burgart, Lawrence J ^a   Mahoney, Michelle R ^a   Windschitl, Harold E ^a   Salim, Muhammad ^a   Wiesenfeld, Martin ^a   Krook, James E ^a   Michalak, John C ^a   Goldberg, Richard M ^a   O'Connell, Michael J ^a   Furth, Alfred F ^a   Sargent, Daniel J ^a   Murphy, Linda M ^a   Hill, Eunice ^a   Riehle, Darren L ^a   Meyers, Cecelia H ^a   Witzig, Thomas E ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA NUCLEOTIDYLEXOTRANSFERASE; FLUOROURACIL; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53; TUMOR MARKER;

APOPTOSIS; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; COLON CANCER; CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MISMATCH REPAIR; NICK END LABELING; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL MODEL; TUMOR LOCALIZATION; ADULT; AGED; BASE MISPAIRING; BIOSYNTHESIS; CELL DIVISION; CLINICAL TRIAL; COLON TUMOR; DISEASE FREE SURVIVAL; DNA REPAIR; EVALUATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENETICS; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PLOIDY; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY;

ADULT; AGED; APOPTOSIS; BASE PAIR MISMATCH; CELL DIVISION; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; DNA REPAIR; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; KI-67 ANTIGEN; MALE; MIDDLE AGED; PLOIDIES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 2442659386     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.10.042     Document Type: Article

References (70)

1. Shulman K, Schilsky RL: Adjuvant therapy of colon cancer. Semin Oncol 22:600-610, 1995
2. Lanza G, Maestri I, Ballotta MR, et al: Relationship of nuclear DNA content to clinicopathologic features in colorectal cancer. Mod Pathol 7:161-165, 1994
3. Greenlee RT, Murray T, Bolden S, et al: Cancer statistics. CA Cancer J Clin 50:7-33, 2000
4. Watanabe T, Wu T-T, Catalano PJ, et al: Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344:1196-1206, 2001
5. Seong J, Chung EJ, Kim H, et al: Assessment of biomarkers in paired primary and recurrent colorectal adenocarcinomas. Int J Radiat Oncol Biol Phys 45:1167-1173, 1999
6. Bedi A, Pasricha PJ, Akhtar AJ, et al: Inhibition of apoptosis during development of colorectal cancer. Cancer Res 55:1811-1816, 1995
7. Takano Y, Saegusa M, Ikenaga M, et al: Apoptosis of colon cancer: Comparison with Ki-67 proliferative activity and expression of p53. J Cancer Res Clin Oncol 122:166-170, 1996
8. Ueda M, Kumagai K, Ueki K, et al: Growth inhibition and apoptotic cell death in uterine cervical carcinoma cells induced by 5-fluorouracil. Int J Cancer 71:668-674, 1997
9. Sinicrope FA, Hart J, Hsu H-A, et al: Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas. Clin Cancer Res 5:1793-1804, 1999
10. Tsujitani S, Shirai H, Tatebe S, et al: Apoptotic cell death and its relationship to carcinogenesis in colorectal carcinoma. Cancer 77:1711-1716, 1996
11. Flohil CC, Janssen PA, Bosman FT: Expression of bcl-2 protein in hyperplastic polyps, adenomas, and carcinomas of the colon. J Pathol 178:393-397, 1996
12. Sinicrope FA, Roddey G, McDonnell TJ, et al: Increased apoptosis accompanies neoplastic development in the human colorectum. Clin Cancer Res 2:1999-2006, 1996
13. Sugao Y, Koji T, Yao T, et al: The incidence of apoptosis during colorectal tumorigenesis. Int J Surg Pathol 8:123-132, 2000
14. Yang H-B, Chow N-H, Sheu B-S, et al: The role of bcl-2 in the progression of the colorectal adenoma-carcinoma sequence. Anticancer Res 19:727-730, 1999
15. Hao XP, Ilyas M, Talbot IC: Expression of bcl-2 and p53 in the colorectal adenoma-carcinoma sequence. Pathobiology 65:140-145, 1997
16. Miyashita T, Krajewski S, Krajewska M, et al: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799-1805, 1994
17. Pietenpol JA, Papadopoulos N, Markowitz S, et al: Paradoxical inhibition of solid tumor cell growth by bcl-2. Cancer Res 54:3714-3717, 1994
18. Kaklamanis L, Savage A, Mortensen N, et al: Early expression of bcl-2 protein in the adenoma-carcinoma sequence of colorectal neoplasia. J Pathol 179:10-14, 1996
19. Kaklamanis L, Savage A, Whitehouse R, et al: Bcl-2 protein expression: Association with p53 and prognosis in colorectal cancer. Br J Cancer 77:1864-1869, 1998
20. Bukholm IK, Nesland JM: Protein expression of p53, p21 (waf1/cip1), bcl-2, bax, cyclin D1 and pRb in human colon carcinomas. Virchows Arch 436:224-228, 2000
21. Buglioni S, D'Agnano I, Cosimelli M, et al: Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: Independent prognostic role of p53 and bcl-2. Int J Cancer 84:545-552, 1999
22. Dumont N: Genetic and epigenetic contributions to colorectal cancer. APMIS 107:711-722, 1999
23. Eshleman JR, Casey G, Kochera ME, et al: Chromosome number and structure both are markedly stable in RER colorectal cancers and are not destabilized by mutation of p53. Oncogene 17:719-725, 1998
24. Curtis LJ, Georgiades IB, White S, et al: Specific patterns of chromosomal abnormalities are associated with RER status in sporadic colorectal cancer. J Pathol 192:440-445, 2000
25. Lindor NM, Burgart LJ, Leontovich O, et al: Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 20:1043-1048, 2002
26. Ribic CM, Sargent DJ, Moore MJ, et al: Tumor microsatellite status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247-257, 2003
27. Ward R, Meagher A, Tomlinson I, et al: Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut 48:821-829, 2001
28. Carder PJ, Cripps KJ, Morris R, et al: Mutation of the p53 gene precedes aneuploid clonal divergence in colorectal carcinoma. Br J Cancer 71:215-218, 1995
29. Carder PJ, Wyllie AH, Purdie CA, et al: Stabilised p53 facilitates aneuploid clonal divergence in colorectal carcinoma. Oncogene 8:1397-1401, 1993
30. Moertel CG, Fleming TR, Macdonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352-358, 1990
31. O'Connell MJ, Martenson JA, Wieand HS, et al: Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331:502-507, 1994
32. Wiesenfeld M, O'Connell MJ, Wieand HS, et al: Controlled clinical trial of interferon-gamma as postoperative surgical adjuvant therapy for colon cancer. J Clin Oncol 13:2324-2329, 1995
33. O'Connell MJ, Mailliard JA, Kahn MJ, et al: Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15:246-250, 1997
34. Garrity MM, Burgart LJ, Riehle DL, et al: Identifying and quantifying apoptosis: Navigating technical pitfalls. Mod Pathol 16:389-394, 2003
35. Cheng L, Pisansky TM, Sebo TJ, et al: Cell proliferation in prostate cancer patients with lymph node metastasis: A marker for progression. Clin Cancer Res 5:2820-2823, 1999
36. Witzig TE, Loprinzi DC, Gonchoroff NJ, et al: DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal cancer. Cancer 68:879-888, 1991
37. Kaplan E, Meier P: Nonparametric estimation for incomplete observations. J Am Stat Assoc 53:457-481, 1958
38. Cox D: Regression models and life tables (with discussion). J R Stat Soc (B) 34:187-220, 1972
39. Grambash PM, Therneau TM: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:515-526, 1994
40. Therneau TM, Atkinson EJ: An introduction to recursive partitioning using the RPART routines. Technical Report Series 61. Rochester, MN, Mayo Clinic, Department of Health Sciences Research, 1997
41. King K, Hwang J, Chau G, et al: Ki-67 expression as a prognostic marker in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 13:273-279, 1998
42. Trihia H, Murray S, Price K, et al: Ki-67 expression in breast carcinoma. Cancer 97:1321-1331, 2003
43. Stavropoulos NE, Filiadis I, Ioachim E, et al: Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer. Anticancer Res 22:3759-3764, 2002
44. Toquet C, Le Neel JC, Guillou L, et al: Elevated (> or =10%) MIB-1 proliferative index correlates with poor outcome in gastric stromal tumor patients: A study of 35 cases. Dig Dis Sci 47:2247-2253, 2002
45. Jones S, Clark G, Koleszar S, et al: Low proliferative rate of invasive node-negative breast cancer predicts for a favorable outcome: A prospective evaluation of 669 patients. Clin Breast Cancer 1:310-314, 2001
46. Itamochi H, Kigawa J, Sugiyama T, et al: Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 100:281-287, 2002
47. Suzuki M, Tsukagoshi S, Saga Y, et al: Assessment of proliferation index with MIB-1 as a prognostic factor in radiation therapy for cervical cancer. Gynecol Oncol 79:300-304, 2000
48. Imdahl A, Jenkner J, Ihling C, et al: Is MIB-1 proliferation index a predictor for response to neoadjuvant therapy in patients with esophageal cancer? Am J Surg 179:514-520, 2000
49. Allegra CJ, Paik S, Colangelo LH, et al: Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: A national cancer institute-national surgical adjuvant breast and bowel project collaborative study. J Clin Oncol 21:241-250, 2003
50. Ewton DZ, Kansra S, Lim S, et al: Insulin-like growth factor-I has a biphasic effect on colon carcinoma cells through transient inactivation of the forkhead1, initially mitogenic, then mediating growth arrest and differentiation. Int J Cancer 98:665-673, 2002
51. Bergers E, van Diest PJ, Baak JPA: Cell cycle analysis of 932 flow cytometric DNA histograms of fresh frozen breast carcinoma material. Cancer 77:2258-2266, 1996
52. Barzanti F, Dal Susino M, Volpi A, et al: Comparison between different cell kinetic variables in human breast cancer. Cell Prolif 33:75-89, 2000
53. Ostrowski ML, Pindur J, Laucirica R, et al: Proliferative activity in invasive breast carcinoma: A comprehensive comparison of MIB-1 immunocytochemical staining in aspiration biopsies to image analytic, flow cytometric and histologic parameters. Acta Cytol 45:965-972, 2001
54. Leonardi E, Dalla Palma P, Reich A, et al: Biological characterisation of superficial bladder cancer by bivariate cytokeratin 7/DNA analysis, flow cytometric assessment of MIB-1, and an immunohistochemical study. Anal Cell Pathol 21:21-33, 2000
55. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61:759-767, 1990
56. Watanabe T, Muto T: Colorectal carcinogenesis based on molecular biology of early colorectal cancer, with special reference to nonpolypoid (superficial) lesions. World J Surg 24: 1091-1097, 2000
57. Bosari S, Moneghini L, Graziani D, et al: Bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. Hum Pathol 26:534-540, 1995
58. Allegra CJ, Parr AL, Wold LE, et al: Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 20:1735-1743, 2002
59. Soong R, Grieu F, Bobbins P, et al: p53 alterations are associated with improved prognosis in distal colonic carcinomas. Clin Cancer Res 3:1405-1411, 1997
60. Bosari S, Viale G, Roncalli M, et al: p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am J Pathol 147:790-798, 1995
61. Kapiteijn E, Liefers GJ, Los LC, et al: Mechanisms of oncogenesis in colon versus rectal cancer. J Pathol 195:171-178, 2001
62. Sun XF, Carstensen JM, Zhang H, et al: Prognostic significance of p53 nuclear and cytoplasmic overexpression in right and left colorectal adenocarcinomas. Eur J Cancer 32A:1963-1967, 1996
63. Bosari S, Viale G, Bossi P, et al: Cytoplasmic accumulation of p53 protein: An independent prognostic indictor in colorectal adenocarcinomas. J Natl Cancer Inst 86:681-687, 1994
64. Goh H, Elnatan J, Low CH, et al: p53 point mutation and survival in colorectal cancer patients: Effect of disease dissemination and tumor location. Int J Oncol 15:491-498, 1999
65. Borresen-Dale AL, Lothe RA, Meling GI, et al: TP53 and long term prognosis in colorectal cancer Mutations in the L3 zinc-binding domain predict poor survival. Clin Cancer Res 4:203-210, 1998
66. Cripps KJ, Purdie CA, Carder PJ, et al: A study of stabilisation of p53 protein versus point mutation in colorectal carcinoma. Oncogene 9:2739-2743, 1994
67. Leahy DT, Salman R, Mulcahy H, et al: Prognostic significance of p53 abnormalities in colorectal carcinoma detected by PCR-SSCP and immunohistochemical analysis. J Pathol 180: 364-370, 1996
68. Bouzourene H, Gervaz P, Cerottini JP, et al: p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer. Eur J Cancer 36:1008-1015, 2000
69. Giatromanolaki A, Stathopoulos GP, Tsiobanou E, et al: Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma. Cancer 86:1421-1430, 1999
70. Zeng ZS, Sarkis AS, Zhang ZF, et al: p53 nuclear overexpression: An independent predictor of survival in lymph node-positive colorectal cancer patients. J Clin Oncol 12:2043-2050, 1994